Price Alert

Barinthus Biotherapeutics (BRNS)

NASDAQ: BRNS · Real-Time Price · USD

1.25

0.11 (9.65%)

At close: Aug 20, 2025, 3:50 PM

Barinthus Biotherapeutics Statistics

Share Statistics

Barinthus Biotherapeutics has 40.35M shares outstanding. The number of shares has increased by 2.95% in one year.

Shares Outstanding	40.35M
Shares Change (YoY)	2.95%
Shares Change (QoQ)	2.02%
Owned by Institutions (%)	n/a
Shares Floating	37.21M
Failed to Deliver (FTD) Shares	288
FTD / Avg. Volume	0.02%

Short Selling Information

The latest short interest is 41.64K, so 0.1% of the outstanding shares have been sold short.

Short Interest	41.64K
Short % of Shares Out	0.1%
Short % of Float	0.16%
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -0.78 and the forward PE ratio is -0.8. Barinthus Biotherapeutics's PEG ratio is 0.04.

PE Ratio	-0.78
Forward PE	-0.8
PS Ratio	3.18
Forward PS	61.7
PB Ratio	0.37
P/FCF Ratio	-1.6
PEG Ratio	0.04

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Barinthus Biotherapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.03, with a Debt / Equity ratio of 0.09.

Current Ratio	8.03
Quick Ratio	8.03
Debt / Equity	0.09
Debt / EBITDA	-0.22
Debt / FCF	-0.4
Interest Coverage	-1282.45

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$142.56K
Profits Per Employee	$-581.66K
Employee Count	105
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	-44K
Effective Tax Rate	0.07%

Stock Price Statistics

The stock price has increased by -9.6% in the last 52 weeks. The beta is -0.72, so Barinthus Biotherapeutics's price volatility has been lower than the market average.

Beta	-0.72
52-Week Price Change	-9.6%
50-Day Moving Average	1.2
200-Day Moving Average	1.05
Relative Strength Index (RSI)	43.37
Average Volume (20 Days)	1,260,306

Income Statement

In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.

Revenue	14.97M
Gross Profit	9.17M
Operating Income	-67.97M
Net Income	-61.07M
EBITDA	-55.37M
EBIT	-61.17M
Earnings Per Share (EPS)	-1.55

Full Income Statement

Balance Sheet

The company has 110.66M in cash and 12.01M in debt, giving a net cash position of 98.66M.

Cash & Cash Equivalents	110.66M
Total Debt	12.01M
Net Cash	98.66M
Retained Earnings	-237.66M
Total Assets	142M
Working Capital	97.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -28.94M and capital expenditures -892K, giving a free cash flow of -29.83M.

Operating Cash Flow	-28.94M
Capital Expenditures	-892K
Free Cash Flow	-29.83M
FCF Per Share	-0.76

Full Cash Flow Statement

Margins

Gross margin is 61.28%, with operating and profit margins of -454.07% and -408%.

Gross Margin	61.28%
Operating Margin	-454.07%
Pretax Margin	-409.03%
Profit Margin	-408%
EBITDA Margin	-369.92%
EBIT Margin	-454.07%
FCF Margin	-199.29%

Dividends & Yields

BRNS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for BRNS is $3, which is 165.5% higher than the current price. The consensus rating is "Buy".

Price Target	$3
Price Target Difference	165.5%
Analyst Consensus	Buy
Analyst Count	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.86
Piotroski F-Score	1